Weifa ASA proposed a dividend OF NOK 0.05 per share for the first quarter of 2016. Final approval of the dividend will be determined by the AGM on 31 May 2016.

Weifa ASA reported earnings results for the first quarter of 2016. For the quarter, the company reported revenue of NOK 96.2 million against NOK 87.4 million, an increase of 10% year-over-year. EBITDA was NOK 16.4 million against NOK 17.4 million a year ago. EBITDA adjusted was NOK 21.9 million against NOK 18.9 million a year ago. Profit before tax from continuing operations was NOK 8.6 million and profit was NOK 6.4 million against profit before tax from continuing operations was NOK 8.9 million and profit was NOK 10.4 million reported a year ago. Cash flow from operating activities was NOK 6.2 million against NOK 0.4 million a year ago. Diluted earnings per share was NOK 0.01 against NOK 0.01 reported a year ago period. Operating profit was NOK 13.3 million against NOK 14.4 million a year ago.

The company expects organic revenue growth and an improved EBITDA margin for 2016 compared with the year before.

The company expects to launch Solvivo - for sore throat in second or third quarter of 2016 and OTC pain granules in third quarter of 2016.